Post-Authorization Activity Table (PAAT) for Stivarga

The PAAT describes post-authorization activity for Stivarga, a product which contains the medicinal ingredient regorafenib (as regorafenib monohydrate). Based on Health Canada's review, the benefit/risk profile of Stivarga is favourable for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-vascular endothelial growth factor therapy, and, if KRAS wild type, an anti-epidermal growth factor receptor therapy. Read more here.